Daiichi Sankyo will build a manufacturing facility in China for its ADC (antibody-drug conjugate) anticancer drug Enhertu. The plant, which will be built in Shanghai, is scheduled to be completed in 2030, and its products will be supplied to China.

According to KoreaBIO, Daiichi Sankyo recently announced plans to build a manufacturing facility for Enhertu in Shanghai, China.

A total of USD 152 million (approximately KRW 220 billion) will be invested in the construction of the facility. Completion is expected in 2030. Daiichi Sankyo explained that the products produced here will be supplied in China.

The new construction plan is attributed to the fact that Enhertu was list